

IN THE CLAIMS:

Claims 1-23 (cancelled)

Claim 24 (currently amended): A method of treating a hormonal dependent benign or malignant disease of the breast or reproductive tract by administration to a human in need of such treatment an intra-muscular injection of a pharmaceutical formulation comprising fulvestrant, a mixture of 10% weight of ethanol per volume of formulation, 10% weight of benzyl alcohol per volume of formulation and 15% weight of benzyl benzoate per volume of formulation ~~30% or less weight of a pharmaceutically acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceutically acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation~~ and a sufficient amount of a castor oil ricinoleate vehicle, whereby a therapeutically significant blood plasma fulvestrant concentration of at least 2.5ngml^{-1} is attained for at least 2 weeks after injection.

Claim 25 (previously added): The method as claimed in claim 24 wherein the benign or malignant disease is breast cancer.

Claim 26 (previously added): The method as claimed in claim 24 wherein the blood plasma fulvestrant concentration is attained for at least 4 weeks after injection.

Claim 27 (previously added): The method as claimed in claim 24 wherein the blood plasma fulvestrant concentration is attained for 2 to 5 weeks after injection.

Claim 28 (currently amended): A method of treating a hormonal dependent benign or malignant disease of the breast or reproductive tract by administration to a human in need of such treatment an intra-muscular injection of a pharmaceutical formulation comprising fulvestrant, a mixture of 10% weight of ethanol per volume of formulation, 10% weight of benzyl alcohol per volume of formulation and 15% weight of benzyl benzoate per volume of formulation ~~30% or less weight of a pharmaceutically acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceutically acceptable non-aqueous ester solvent~~

~~miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate castor oil vehicle whereby the formulation comprises at least 45mgml⁻¹ of fulvestrant.~~

Claims 29 – 44 (cancelled).

Claim 45 (previously added): The method as claimed in claim 24 or 28 wherein the total volume of the formulation administered to said human is 6ml or less, and the concentration of fulvestrant in said formulation is at least 45mgml⁻¹.

Claim 46 (previously added): The method as claimed in claim 24 or 28 wherein the total volume of the formulation administered to said human is 6ml or less, and the total amount of fulvestrant in said volume of formulation is 250mg or more.

Claim 47 (currently amended): The method as claimed in claim 46 wherein the total volume of the formulation is from 5 to 5.25ml, and the total amount of fulvestrant in said volume of formulation is 250mg.

Claim 48 – 50 (cancelled).